Forte Biosciences Past Earnings Performance

Past criteria checks 0/6

Forte Biosciences's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 13.4% annually.

Key information

-2.4%

Earnings growth rate

60.5%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-210.8%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Forte Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:37T Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-361720
31 Mar 240-321221
31 Dec 230-311122
30 Sep 230-301021
30 Jun 230-24816
31 Mar 230-18910
31 Dec 220-1486
30 Sep 220-1284
30 Jun 220-1789
31 Mar 220-19811
31 Dec 210-22814
30 Sep 210-23716
30 Jun 210-20614
31 Mar 210-49512
31 Dec 200-46410
30 Sep 200-4338
30 Jun 200-3925
31 Mar 200-523
31 Dec 190-413

Quality Earnings: 37T is currently unprofitable.

Growing Profit Margin: 37T is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 37T is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare 37T's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 37T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).


Return on Equity

High ROE: 37T has a negative Return on Equity (-210.82%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies